𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies

✍ Scribed by Ezra, Yossef; Rose, Michal; Eldor, Amiram

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
511 KB
Volume
51
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

✦ Synopsis

Thrombotic thrombocytopenic purpura (TrP) is a severe multisystem disorder of unknown pathogenesis, with preference to women. The mortality rate of patients with TTP was 90% until the introduction of plasma therapy that Increased the survival rate to 70-80%, with minimal or no sequelae. Of the survivors, 3040% suffer from relapses, often in association with precipitating factors such as infections, surgery, and pregnancy. Women who are either pregnant or in the postpartum period make up 10-25% of TTP patients, and once the disease occurs during a pregnancy, it tends to recur in subsequent ones. We treated five women who suffered at least one l T P episode during pregnancy. They had a total of 16 pregnancies, eight of which were complicated by TTP. They suffered seven additional TTP episodes that were not associated with pregnancy. We assessed the severity of each TTP episode with a scoring system used In our previous studies.

Presented is the course of their disease and their pregnancies, and guidelines for the management and prevention of TTP during pregnancy are provided.

o iges wiisy-Liss. inc.

πŸ“œ SIMILAR VOLUMES

Evaluation of women with clinically susp
Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy
✍ Johnny R. McMinn; James N. George πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 95 KB

## Abstract Thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome (TTP‐HUS) is more common in women, and commonly occurs during pregnancy and the immediate postpartum period. An important clinical issue is the distinction of TTP‐HUS from the more common obstetric complications, preeclampsia

Rituximab therapy for thrombotic thrombo
Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders
✍ James N. George; Robert D. Woodson; Joseph E. Kiss; Kiarash Kojouri; Sara K. Ves πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 101 KB

## Abstract The rationale for immunosuppressive therapy of thrombotic thrombocytopenic purpura (TTP) was established by observations that TTP may be caused by autoantibodies to ADAMTS13. Patients with high‐titer autoantibodies to ADAMTS13 may have a higher mortality, and survivors may require prolo